Supplementary Figure S1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Real-world analysis shows that changes in ctDNA predict long-term clinical benefit from immune checkpoint inhibitors in pan-cancer patients, highlighting its potential value.
Key Points
Changes in ctDNA tumor fraction predict clinical benefit from immune checkpoint inhibitors, revealing the importance of monitoring during treatment.
The study found a direct link between ctDNA methylation levels and patient outcomes, indicating effective treatment response.
Observational analysis across various cancer types shows how ctDNA can be a reliable biomarker for therapy effectiveness.
These findings may enable improved patient selection for immune checkpoint therapies, establishing ctDNA monitoring as a valuable tool.